Cadrenal Therapeutics, Inc. reported a net loss of $3.7 million for the second quarter ended June 30, 2025, compared to a net loss of $2.4 million for the same period in 2024. Research and development expenses for Q2 2025 were $1.1 million, a decrease from $1.3 million in Q2 2024, while general and administrative expenses increased to $2.7 million from $1.2 million.
The company's cash and cash equivalents totaled $5.6 million as of June 30, 2025, down from $10.0 million at December 31, 2024. Approximately 2.0 million shares of common stock were outstanding as of the quarter's end.
Key corporate updates included the announcement in August 2025 of plans to initiate a clinical trial for tecarfarin in patients with ESKD transitioning to dialysis. Additionally, effective June 30, 2025, Cadrenal was added to multiple Russell indexes, including the Russell 3000E and Russell Microcap families, which can broaden the company's shareholder base.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.